Press Releases

15/06/2017 OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127

14/06/2017 OSE Immunotherapeutics Announces Results of 2017 Annual Meeting of Shareholders

12/06/2017 OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration with Memorial Sloan Kettering Cancer Center in New York

23/05/2017 Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist

22/05/2017 OSE Immunotherapeutics Strengthens R&D Team with Appointment of Two Senior Talented Immunologists

18/05/2017 OSE Immunotherapeutics to Present at Annual Sachs Immuno-Oncology: BD&L and Investment Forum

15/05/2017 OSE Immunotherapeutics Presents New Data on Anti-SIRPa (Effi-DEM)

05/04/2017 OSE Immunotherapeutics Presented New Data at AACR 2017 on OSE-172 (Effi-DEM)

28/03/2017 2016 Results: Significant Milestones, First Profit, More Growth to Come

21/02/2017 OSE Immunotherapeutics New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)

07/02/2017 OSE Immunotherapeutics to Present Corporate Overview at Upcoming BIO CEO & Investor Conference

24/01/2017 OSE Immunotherapeutics Announces that the IDMC Recommends Continuation of Pivotal Phase 3 Clinical Trial of Tedopi®

04/01/2017 OSE Immunotherapeutics to present at Biotech Showcase™ 2017 Conference

31/05/2016 OSE Pharma and Effimune shareholders approve merger to create OSE Immunotherapeutics

19/05/2016 OSE Pharma and Effimune announce the launch of a non-interventional study in hepatocellular carcinoma

18/05/2016 Dominique Costantini, Co-Founder of OSE Pharma, invited to « Bpifrance Inno Génération »

12/05/2016 Presentation of the future entity OSE Immunotherapeutics at the 2nd « Annual Immuno-Oncology: BD&L and Investment Forum »

11/05/2016 Effimune and OSE Pharma announce the online publication of Preclinical efficacy data for FR104

1 2 3 4 5 6 7 8 9 10 11 12 13